Printer Friendly

BERG & LOUCKS APPOINTED AFFYMETRIX DIRECTORS

 PALO ALTO, Calif., July 1 /PRNewswire/ -- Affymetrix Inc. announced today the appointment of Paul Berg, Ph.D., and Vernon R. Loucks Jr. to its board of directors. Affymetrix is developing innovative DNA-based systems based on the Affymax VLSIPS(TM) DNA chip technology for the emerging genetic analysis market and the clinical diagnostic and research instrumentation markets.
 Berg is the Willson Professor of Biochemistry and director of the Beckman Center for Molecular and Genetic Medicine at the Stanford University School of Medicine. Berg received the Nobel Prize in chemistry in 1980 for his work on the biochemistry of nucleic acids, particularly recombinant DNA, and in 1983 received the National Medal of Science. He is a member of the U.S. National Academy of Sciences and its Institute, the American Academy of Arts and Sciences and a foreign member of the Royal Society of London. Berg has been a scientific advisor to Affymetrix since its inception.
 Loucks is chairman and chief executive officer of Baxter International Inc., the leading worldwide marketer and manufacturer of health-care products, systems and services. Loucks serves as a director of The Dun & Bradstreet Corp., The Quaker Oats Co. and Anheuser-Busch Companies Inc. In addition, he is a senior fellow of the Yale Corporation.
 Affymetrix has established an independent board of directors as part of the process of becoming an independent operating company. Affymetrix intends to secure independent financing during 1993.
 The Affymetrix board of directors also includes Alejandro Zaffaroni, Ph.D., chairman and chief executive officer of Affymax N.V. and co-chairman of Alza Corp.; John D. Diekman, Ph.D., president and chief operating officer of Affymax N.V. and chairman of the board of Affymetrix; David B. Singer, president and chief executive officer of Affymetrix; and Stephen P.A. Fodor, Ph.D., chief technical officer and scientific director of Affymetrix.
 Affymetrix is developing products to enable researchers and clinicians to analyze genetic information rapidly and cost-effectively. Affymetrix is directing its efforts toward the development of very large arrays of DNA probes, or "chips," for the research laboratory and clinical markets. Affymetrix is a wholly owned subsidiary of Affymax N.V. Affymax (NASDAQ: AFMXF) is developing new technologies to accelerate the pace of drug delivery.
 -0- 7/1/93
 /CONTACT: Diana Kapp of Affymetrix, 415-496-2379/
 (AFMXF)


CO: Affymetrix Inc.; Affymax N.V. ST: California IN: MTC SU: PER

TM-SA -- SJ003 -- 7525 07/01/93 08:30 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 1, 1993
Words:400
Previous Article:TIME REALLY IS MONEY! EXECUTIVE SURVEY SHOWS EMPLOYEES EAGER TO TRADE OTHER BENEFITS FOR MORE VACATION
Next Article:CHAPLET PERIPHERALS ANNOUNCES NEW PRODUCT LINES; TOTAL INTEGRATED PERIPHERAL TECHNOLOGY AND SOLUTION FOR PORTABLE COMPUTING DEVICES
Topics:


Related Articles
BAXTER PRESIDENT TO HEAD NEW BIOTECH VENTURE; COMPANY NAMES NEW PRESIDENT
BAXTER TO EXPLORE ISSUING EQUITY SECURITY TIED TO ALTERNATE SITE BUSINESS
LOUCKS: BAXTER POSITIONED FOR HEALTH REFORM; COMPANY HELPED U.S. HOSPITALS REDUCE COSTS BY $190 MILLION IN 1992
AFFYMETRIX APPOINTS TOP MANAGEMENT
JOHN YOUNG APPOINTED AFFYMETRIX DIRECTOR
LOUCKS ANNOUNCES THAT BAXTER COO AND PRESIDENT JAMES R. TOBIN WILL RESIGN; WILBUR H. GANTZ, A DIRECTOR, RESIGNS SEPARATELY
Baxter Announces Board Appointments to its Planned Cardiovascular Spin-Off Company.
Affymetrix Announces Formation of New Genomics Company: Perlegen Sciences.
United States Attorney Announces the Appointment of New First Assistant U.S. Attorney.
Former Baxter Leader Vern Loucks Joins Pain Therapeutics' Board of Directors.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters